Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis
by: Anders Perner, Nicolai Haase, Anne B. Guttormsen, Jyrki Tenhunen, Gudmundur Klemenzson, Anders Åneman, Kristian R. Madsen, Morten H. Møller, Jeanie M. Elkjær, Lone M. Poulsen, Asger Bendtsen, Robert Winding, Morten Steensen, Pawel Berezowicz, Peter Søe-Jensen, Morten Bestle, Kristian Strand, Jørgen Wiis, Jonathan O. White, Klaus J. Thornberg, Lars Quist, Jonas Nielsen, Lasse H. Andersen, Lars B. Holst, Katrin Thormar, Anne-Lene Kjældgaard, Maria L. Fabritius, Frederik Mondrup, Frank C. Pott, Thea P. Møller, Per Winkel, Jørn Wetterslev
N Engl J Med In New England Journal of Medicine, Vol. 367, No. 2. (27 June 2012), pp. 124-134, doi:10.1056/nejmoa1204242 Key: citeulike:11866879
Formatted Citation
Show HTML
Likes (beta)
This copy of the article hasn't been liked by anyone yet.
View FullText article
Abstract
Intravenous fluids are the mainstay of treatment for patients with hypovolemia due to severe sepsis. Colloid solutions are used to obtain rapid and lasting circulatory stabilization, but there are limited data to support this practice.1 The Surviving Sepsis Campaign guidelines recommend the use of either colloids or crystalloids,2 but high-molecular-weight hydroxyethyl starch (HES) may cause acute kidney failure in patients with severe sepsis, as observed in two randomized trials.3,4 Those trials had substantial limitations, and participants received HES solutions with a molecular weight of 200 kD and a substitution ratio (the number of hydroxyethyl groups per glucose molecule) of . . .
Orwenau's tags for this article
Citations (CiTO)
No CiTO relationships defined
There are no reviews yet
